Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kristina Iribarren, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

102 Citaten (Scopus)

Samenvatting

ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Originele taal-2Engels
TijdschriftOncoImmunology
Volume5
Nummer van het tijdschrift3
DOI's
StatusGepubliceerd - 3 mrt. 2016
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit